BIOGEN INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
BIOGEN INC. (BIIB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $36.10 million as of 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-06
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $36.10M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $34.40M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $36.10M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $37.20M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $36.10M 10-K · filed 2026-02-06 |
| 2024-12-31 | $34.40M 10-K · filed 2026-02-06 |
| 2023-12-31 | $36.10M 10-K · filed 2025-02-12 |
| 2022-12-31 | $37.20M 10-K · filed 2024-02-14 |
| 2021-12-31 | $31.70M 10-K · filed 2023-02-15 |
| 2020-12-31 | $23.30M 10-K · filed 2022-02-03 |
| 2019-12-31 | $23.80M 10-K · filed 2021-02-03 |
| 2018-12-31 | $25.80M 10-K · filed 2020-02-06 |
| 2017-12-31 | $26.90M 10-K · filed 2019-02-06 |
| 2016-12-31 | $61.50M 10-K · filed 2018-02-01 |
| 2015-12-31 | $63.80M 10-K · filed 2017-02-02 |
| 2014-12-31 | $86.00M 10-K · filed 2016-02-03 |
| 2013-12-31 | $85.00M 10-K · filed 2015-02-04 |
| 2012-12-31 | $58.60M 10-K · filed 2014-02-06 |
| 2011-12-31 | $54.70M 10-K · filed 2013-02-05 |
| 2010-12-31 | $64.40M 10-K · filed 2012-02-03 |
| 2009-12-31 | $60.80M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |